Benitec Biopharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Benitec Biopharma Inc. (BNTC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.79% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-09-14
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 4.09%, a 2.51% increase year-over-year.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-09-30 was 3.99%.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2026 was 3.79%, a 8.01% decline from fiscal 2025.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.12%, a 0.00% change from fiscal 2024.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.12%, a 4.04% increase from fiscal 2023.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.96%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.79% 10-K · filed 2026-09-14 | |||
| 2026-03-31 | 3.78% 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 3.78% 10-Q · filed 2026-02-12 | |||
| 2025-09-30 | 4.09% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 4.12% 10-K · filed 2026-09-14 | |||
| 2025-03-31 | 4.13% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 4.13% 10-Q · filed 2026-02-12 | |||
| 2024-09-30 | 3.99% 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 4.12% 10-K/A · filed 2026-03-20 | |||
| 2023-06-30 | 3.96% 10-K · filed 2024-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |